Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
News
In Case You Missed It: UAE agricultural deliveries and some Swedish lithium
Health & Biotech
AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks
Health & Biotech
ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health
News
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!
News
Market Highlights: Wall Street slips, common mistakes in stock trading, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Mesoblast crashes 54pc after FDA says it needs more data for approval
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Investors in pain as ASX falls 1.69% to 50-day low
News
In Case You Missed It: Germanium and gallium lead the pack followed by new drug data and lithium
News
ASX Small Cap Lunch Wrap: Who’s got their all-seeing eye on everything today?
Health & Biotech
ASX Health Stocks: AdAlta jumps 40pc after its fibrosis drug shows ‘potential efficacy’ in humans
News
Top 10 at 10: ASX stock jumps on the germanium, gallium bandwagon, gains 45pc
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
News
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
Health & Biotech
